top of page

Houston Oncology Summit: Talking KRAS & pan-RAS inhibition with MD Anderson’s Ferdinandos Skoulidis

Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and why he believes the theoretical potential for pan-RAS inhibitors is substantial.



Brought to you by:


Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page